{"id":"hu-014","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Telomerase is an enzyme that maintains telomeres, the protective caps on the ends of chromosomes. By inhibiting telomerase, HU-014 aims to induce apoptosis in cancer cells with high telomerase activity, thereby exerting its anti-tumor effects.","oneSentence":"HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:28.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT05964257","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huons Biopharma","startDate":"2023-07-25","conditions":"Benign Masseteric Hypertrophy","enrollment":188},{"nctId":"NCT05289921","phase":"PHASE3","title":"To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2022-03-04","conditions":"Post Stroke Upper Limb Spasticity","enrollment":198},{"nctId":"NCT04415346","phase":"PHASE1","title":"A Single Center, Phase I Clinical Trial to Evaluate the Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity","status":"UNKNOWN","sponsor":"Huons Co., Ltd.","startDate":"2019-11-06","conditions":"Post Stroke Upper Limb Spasticity","enrollment":13},{"nctId":"NCT04081402","phase":"PHASE3","title":"A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines","status":"UNKNOWN","sponsor":"Huons Co., Ltd.","startDate":"2018-11-01","conditions":"Crow's Feet Lines","enrollment":290},{"nctId":"NCT02961673","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-09","conditions":"Glabellar Lines","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HU-014","genericName":"HU-014","companyName":"Huons Co., Ltd.","companyId":"huons-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}